Go to deals
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

GeneTech is a provider of non-invasive prenatal genetic tests (NIPT). The tests can only be taken at facilities certified by the Japanese Association of Medical Sciences. As a result of these efforts, GeneTech has carried out more than 90% of the NIPT tests conducted in Japan. Additionally, based on the achievements and experience accumulated, the firm has delivered various academic information and peripheral services to medical institutions.

Incorporated in 2014, Eurofins Clinical Testing Holding Lux S.à r.l. is a global clinical test service provider based in Luxembourg.

Founded in 1951, Noritsu Koki is a Tokyo Stock First Section listed public conglomerate specializing in manufacturing and healthcare businesses.

Oaklins’ team in Japan acted as the exclusive financial advisor to Noritsu Koki Co., Ltd. in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Taro  Okayama

Taro Okayama

Managing Director

Tokyo, Japan
Oaklins SXA
 Yasuhiro  Yasumuro

Yasuhiro Yasumuro

Director

Tokyo, Japan
Oaklins SXA

Related deals

Maginnis Orthodontics has been acquired by Smile Doctors
Healthcare

Maginnis Orthodontics has been acquired by Smile Doctors

Maginnis Orthodontics, Inc. has been sold to Smile Doctors, LLC.

Learn more
Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Learn more